Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1613 1614
This examiner grants 39% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19279603 | TAMPER RESISTANT DOSAGE FORMS | Final Rejection | PURDUE PHARMACEUTICALS L.P. |
| 18208029 | POLYMERS AND USES THEREOF | Non-Final OA | Hoffmann-La Roche Inc. |
| 17936208 | Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 18043764 | PATCH AND PRODUCTION METHOD THEREOF | Final Rejection | KANEKA CORPORATION |
| 18292286 | COMPOSITION FOR LIGHTENING KERATIN FIBRES, COMPRISING A PEROXYGENATED SALT, CARBONATE AND/OR AMMONIUM BICARBONATE AND AT LEAST 1% OF A POLYPHOSPHORUS DERIVATIVE | Non-Final OA | L'Oreal |
| 19060024 | DISINFECTANT COMPOSITION | Non-Final OA | Whiteley Corporation Pty. Ltd. |
| 16620079 | POWDERED THICKENER MAINTAINING ITS EXTENSIONAL PROPERTIES WHEN RECONSTITUTED AND FOR PROMOTING SAFE SWALLOWING BY INDIVIDUALS WITH DYSPHAGIA | Final Rejection | SOCIETE DES PRODUiTS NESTLE S.A |
| 18044877 | PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE AND A PROTEIN | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18685853 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | Non-Final OA | The Board of Trustees of the University of Illinois |
| 17796606 | TREATMENT OR PREVENTION METHOD FOR CHRONIC HEART FAILURE | Final Rejection | Japan Tobacco Inc. |
| 18646212 | PERCUTANEOUS ABSORPTION FORMULATION FOR TREATING SLEEP DISORDERS | Non-Final OA | SINSIN PHARM CO., LTD. |
| 18041420 | A STORAGE STABLE INSECTICIDAL COMPOSITION | Final Rejection | UPL Limited |
| 18685051 | MAGNESIUM OXIDE TABLETS | Non-Final OA | SETOLAS Holdings, Inc. |
| 18171406 | Intravaginal Ring Device for the Delivery of Aromatase Inhibitor | Non-Final OA | Celanese EVA Performance Polymers LLC |
| 18489133 | PHARMACEUTICAL COMPOSITION | Final Rejection | MEXICHEM FLUOR S.A. DE C.V. |
| 18287381 | DIETARY COMPOSITIONS TO EXTEND LONGEVITY WHILE MAXIMIZING STRENGTH AND FUNCTION | Non-Final OA | ISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS |
| 18552434 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | Non-Final OA | Impact Therapeutics (Shanghai), Inc |
| 18204780 | NANOSPHERE AND USE THEREOF | Final Rejection | CHANG GUNG UNIVERSITY |
| 18265042 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Non-Final OA | TOWA PHARMACEUTICAL CO., LTD. |
| 18203429 | SEQUENTIAL ADMINISTRATION OF PARTITIONED ABSORPTION ASPIRIN OR ACTIVE ASPIRIN DERIVATIVE AND COX-2 INHIBITOR | Final Rejection | CELSPRIN LLC |
| 18201107 | PROCESS FOR MAKING A SOLVENT-FREE NANODISPERSION FOR FAT-SOLUBLE VITAMINS AND NUTRACEUTICALS | Final Rejection | MALAYSIAN PALM OIL BOARD (MPOB) |
| 18031784 | DENTAL KIT COMPRISING A DENTAL ALIGNER OR A MOUTH TRAY AND DISSOLVABLE FILMS | Non-Final OA | BSOLVE LIMITED |
| 18030439 | CANNABINOID-CONTAINING COMPOSITIONS AND USE FOR TREATING AND PREVENTING DISEASES | Final Rejection | Max Biology Co. Ltd. |
| 18020234 | A COMPOSITON COMPRISING MICROCAPSULES | Final Rejection | TEAGASC -THE AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY |
| 17251802 | AMPHIPHILIC POLYMERS, PROCESS OF PREPARING SAME AND USES THEREOF | Final Rejection | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. |
| 17776723 | PROCESS FOR PRODUCING AN ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION WITH COLONIC DELIVERY | Final Rejection | Shanghai Ethypharm Pharmaceuticals Co. Ltd. |
| 17916285 | INHIBITORS OF THE INTERACTION OF THE UPAR/FPRS RECEPTORS | Final Rejection | ORPHA BIOTECH S.R.L. |
| 17889009 | POLYMERIC COMPOSITIONS FOR SUSTAINED DELIVERY OF VMAT2 INHIBITORS | Final Rejection | Foresee Pharmaceuticals Co., Ltd. |
| 17383941 | METHODS AND DEVICES FOR REPAIR OF CRUSHED PERIPHERAL NERVE INJURIES WITH ERYTHROPOIETIN | Final Rejection | Shu-Tung and Alice Li Foundation Inc. |
| 17311572 | VITAMIN D NANO-EMULSIONS AND USES THEREOF | Final Rejection | Lipicare Pharmaceuticals Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy